424 related articles for article (PubMed ID: 22661587)
21. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R
Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278
[TBL] [Abstract][Full Text] [Related]
22. Nilotinib in advanced gastrointestinal stromal tumors after imatinib and sunitinib therapy.
Dizdar O; Yalcin S
Hepatogastroenterology; 2011; 58(112):2012-4. PubMed ID: 22024073
[TBL] [Abstract][Full Text] [Related]
23. Successful treatment with sunitinib in a young patient with metastatic gastrointestinal stromal tumor after failure on adjuvant imatinib.
Kapoor R; Khosla D; Kumar P; Kumar N; Bera A
J Cancer Res Ther; 2011; 7(4):491-3. PubMed ID: 22269418
[No Abstract] [Full Text] [Related]
24. Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib.
Paz-Ares L; García del Muro X; Grande E; González P; Brosa M; Díaz S
Clin Transl Oncol; 2008 Dec; 10(12):831-9. PubMed ID: 19068454
[TBL] [Abstract][Full Text] [Related]
25. Clinical efficacy and safety of sunitinib after imatinib failure in Japanese patients with gastrointestinal stromal tumor.
Matsumoto K; Sawaki A; Mizuno N; Hara K; Hijioka S; Niwa Y; Tajika M; Kawai H; Kondo S; Yamao K
Jpn J Clin Oncol; 2011 Jan; 41(1):57-62. PubMed ID: 20858619
[TBL] [Abstract][Full Text] [Related]
26. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
Heinrich MC; Maki RG; Corless CL; Antonescu CR; Harlow A; Griffith D; Town A; McKinley A; Ou WB; Fletcher JA; Fletcher CD; Huang X; Cohen DP; Baum CM; Demetri GD
J Clin Oncol; 2008 Nov; 26(33):5352-9. PubMed ID: 18955458
[TBL] [Abstract][Full Text] [Related]
27. Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial.
Kurokawa Y; Honma Y; Sawaki A; Naito Y; Iwagami S; Komatsu Y; Takahashi T; Nishida T; Doi T
Ann Oncol; 2022 Sep; 33(9):959-967. PubMed ID: 35688358
[TBL] [Abstract][Full Text] [Related]
28. Nilotinib is effective in imatinib and sunitinib resistant GIST: a case report.
Dizdar O; Yalcin S
Hepatogastroenterology; 2011; 58(107-108):859-60. PubMed ID: 21830404
[TBL] [Abstract][Full Text] [Related]
29. Sunitinib: new drug. For some gastrointestinal stromal tumours.
Prescrire Int; 2007 Aug; 16(90):138-41. PubMed ID: 17724833
[TBL] [Abstract][Full Text] [Related]
30. Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib.
Ruka W; Rutkowski P; Szawłowski A; Nowecki Z; Debiec-Rychter M; Grzesiakowska U; Dziewirski W; Siedlecki JA; Michej W
Eur J Surg Oncol; 2009 Jan; 35(1):87-91. PubMed ID: 18289826
[TBL] [Abstract][Full Text] [Related]
31. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD
Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424
[TBL] [Abstract][Full Text] [Related]
32. Second line therapies for the treatment of gastrointestinal stromal tumor.
Joensuu H
Curr Opin Oncol; 2007 Jul; 19(4):353-8. PubMed ID: 17545799
[TBL] [Abstract][Full Text] [Related]
33. Advances in the treatment of gastrointestinal stromal tumours.
Judson I; Demetri G
Ann Oncol; 2007 Sep; 18 Suppl 10():x20-4. PubMed ID: 17761719
[TBL] [Abstract][Full Text] [Related]
34. A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours.
Contreras-Hernández I; Mould-Quevedo JF; Silva A; Salinas-Escudero G; Villasís-Keever MA; Granados-García V; Dávila-Loaiza G; Petersen JA; Garduño-Espinosa J
Br J Cancer; 2008 Jun; 98(11):1762-8. PubMed ID: 18506179
[TBL] [Abstract][Full Text] [Related]
35. Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series.
Rutkowski P; Magnan H; Chou AJ; Benson C
BMC Cancer; 2017 Nov; 17(1):717. PubMed ID: 29110655
[TBL] [Abstract][Full Text] [Related]
36. Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib.
Shinagare AB; Jagannathan JP; Kurra V; Urban T; Manola J; Choy E; Demetri GD; George S; Ramaiya NH
Eur J Cancer; 2014 Mar; 50(5):981-6. PubMed ID: 24388774
[TBL] [Abstract][Full Text] [Related]
37. [Responses to treatment and switching tyrosine kinase inhibitors in gastrointestinal stromal tumor(GIST)].
Nishida T; Wakasugi M; Ueshima S
Gan To Kagaku Ryoho; 2012 Sep; 39(9):1330-5. PubMed ID: 22996768
[TBL] [Abstract][Full Text] [Related]
38. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
Mir O; Cropet C; Toulmonde M; Cesne AL; Molimard M; Bompas E; Cassier P; Ray-Coquard I; Rios M; Adenis A; Italiano A; Bouché O; Chauzit E; Duffaud F; Bertucci F; Isambert N; Gautier J; Blay JY; Pérol D;
Lancet Oncol; 2016 May; 17(5):632-41. PubMed ID: 27068858
[TBL] [Abstract][Full Text] [Related]
39. Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor.
Komatsu Y; Ohki E; Ueno N; Yoshida A; Toyoshima Y; Ueda E; Houzawa H; Togo K; Nishida T
Jpn J Clin Oncol; 2015 Nov; 45(11):1016-22. PubMed ID: 26373318
[TBL] [Abstract][Full Text] [Related]
40. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib.
Montemurro M; Schöffski P; Reichardt P; Gelderblom H; Schütte J; Hartmann JT; von Moos R; Seddon B; Joensuu H; Wendtner CM; Weber E; Grünwald V; Roth A; Leyvraz S
Eur J Cancer; 2009 Sep; 45(13):2293-7. PubMed ID: 19467857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
